Early change in tumour size predicts overall survival in patients with first-line metastatic breast cancer
详细信息 查看全文
- 作者：Sonya C. Tatea ; tate_sonya@network.lilly.com" class="auth_mail" title="E-mail the corresponding author ; Valerie Andreb ; andre_valerie@lilly.com" class="auth_mail" title="E-mail the corresponding author ; Nathan Enasc ; enas_nathan_h@lilly.com" class="auth_mail" title="E-mail the corresponding author ; Benjamin Ribbad ; benjamin.ribba@inria.fr" class="auth_mail" title="E-mail the corresponding author ; Ivelina Gueorguievaa ; gueorguieva_ivelina@lilly.com" class="auth_mail" title="E-mail the corresponding author
- 关键词：Survival analysis ; Breast cancer ; Gemcitabine ; Paclitaxel ; Docetaxel ; Capecitabine ; Mathematical model ; Treatment outcome ; Response evaluation criteria in solid tumours
- 刊名：European Journal of Cancer
- 出版年：2016
- 出版时间：October 2016
- 年：2016
- 卷：66
- 期：Complete
- 页码：95-103
- 全文大小：918 K
文摘
- •
We establish a drug-disease model for first-line metastatic breast cancer (mBC).
- •
We model the tumour growth inhibitory effects of gemcitabine combotherapy.
- •
We relate model-predicted change in tumour size (CTS) to overall survival.
- •
CTS at week 8 predicts survival in mBC.
- •
Late phase outcome may be predicted from early phase II data, facilitating timely go/no-go decision making.